Zhongke Meiling Cryogenics (835892)

Search documents
北交所专题:流动性显著改善,市场认可度不断提升
Guoxin Securities· 2025-06-27 11:40
Investment Rating - The report maintains an "Outperform" rating for the North Exchange market [5] Core Insights - The liquidity of the North Exchange has significantly improved, and its market recognition is continuously increasing [1][2] - In 2024, the total operating revenue of North Exchange A-shares reached 181.981 billion, with a net profit of 11.256 billion [1][15] - The average operating revenue per company in 2024 was 0.682 billion, with a net profit average of 0.042 billion [1][15] - The North Exchange A-shares have shown a stable revenue average of over 6.8 billion in the past three years [1][32] Summary by Sections Overall Performance of North Exchange A-shares - In 2024, the total operating revenue was 1819.81 billion, and the net profit was 112.56 billion [1][15] - The average revenue per company was 6.82 billion, and the average net profit was 0.42 billion [1][15] - The highest revenue and net profit in 2024 were recorded by Better Ray, with revenues of 14.237 billion and net profits of 0.946 billion [25][27] Comparison with Other Markets - The average revenue of North Exchange A-shares has remained stable above 6.8 billion over the past three years, while the average revenue of the dual innovation board is above 20.10 billion [1][32] - The net profit average for North Exchange A-shares has fluctuated between 0.42 and 0.68 billion over the past five years, compared to 1.02 to 1.61 billion for the registered system entrepreneurial board [1][32] Valuation Metrics - The PE-TTM value of North Exchange A-shares has surpassed the main board starting in 2024, indicating improved market attractiveness [2][39] - The PB value of North Exchange A-shares has exceeded that of the main board and is comparable to the registered system entrepreneurial board, reflecting rapid improvement in asset pricing capability [2][42] Liquidity Indicators - The trading volume of North Exchange has significantly increased since November 2023, with 2024 trading volume reaching 29735.71 billion [2][50] - The turnover rate of North Exchange stocks has consistently been higher than that of the dual innovation board since November 2023 [2][50] R&D Indicators - The average R&D expenditure for North Exchange A-shares in 2024 was 0.3223 billion, with the highest being 0.77206 billion by Better Ray [28] - The market R&D ratio has significantly increased, reaching 74.5346% in 2024, surpassing Shenzhen A-shares and approaching Shanghai A-shares levels [3][59] Industry Breakdown - The top five industries by total revenue in North Exchange A-shares in 2024 were power equipment, basic chemicals, machinery, automotive, and computers [3] - The highest gross margin industries included machinery, pharmaceuticals, computers, power equipment, and automotive [3]
中科美菱换手率28.19%,龙虎榜上榜营业部合计净买入473.53万元
Zheng Quan Shi Bao Wang· 2025-06-06 13:03
Group 1 - Zhongke Meiling (835892) experienced a 4.27% increase in stock price, with a turnover rate of 28.19% and a trading volume of 176 million yuan, showing a volatility of 14.03% [2] - The stock was listed on the North Exchange's daily turnover list due to its turnover rate, with a net buying amount of 4.7353 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction amount of 40.0273 million yuan, with a buying amount of 22.3813 million yuan and a selling amount of 17.6460 million yuan, resulting in a net buying of 4.7353 million yuan [2] Group 2 - The largest buying brokerage was Haitong Securities Co., Ltd. Guangzhou Dongfeng West Road branch, with a buying amount of 9.0847 million yuan, while the largest selling brokerage was Huaxi Securities Co., Ltd. Meishan Hubin Road branch, with a selling amount of 4.5821 million yuan [2] - Over the past six months, Zhongke Meiling has appeared on the turnover list nine times, with an average price drop of 4.28% the day after being listed and an average drop of 9.96% over the following five days [2]
中科美菱(835892) - 关于使用自有闲置资金购买理财产品的进展公告
2025-06-04 16:00
证券代码:835892 证券简称:中科美菱 公告编号:2025-060 中科美菱低温科技股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权自有资金理财情况 (一)购买理财产品的审议情况 为提高公司资金使用效益,增加现金资产收益,实现股东利益最大化,公司 第三届董事会第三十一次会议、2024 年第二次临时股东大会,审议通过了《关 于使用自有闲置资金进行投资理财的议案》,在保证日常经营运作资金需求、有 效控制投资风险的前提下,公司及下属子公司拟使用自有闲置资金最高不超过 2 亿元人民币(该额度可以滚动使用)进行银行理财产品投资,投资期限为自 2024 年第二次临时股东大会审议通过之日起一年内有效。 具体内容详见公司于 2024 年 12 月 11 日、12 月 27 日在北京证券交易所网 站披露的《关于使用自有闲置资金进行投资理财的公告》(公告编号:2024-071) 《2024 年第二次临时股东大会决议公告》(公告编号:2024-074)。 ...
中科美菱龙虎榜:营业部净买入115.35万元
Zheng Quan Shi Bao Wang· 2025-05-27 09:26
Group 1 - Zhongke Meiling (835892) experienced a decline of 9.08% with a turnover rate of 31.48% and a trading volume of 185 million yuan, showing a fluctuation of 4.46% [2] - The stock was listed on the North Exchange's daily trading information due to its turnover rate reaching 31.48%, with a net buying amount of 1.1535 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction amount of 45.2209 million yuan, with a buying amount of 23.1872 million yuan and a selling amount of 22.0337 million yuan, resulting in a net buying of 1.1535 million yuan [2] Group 2 - The largest buying brokerage was Huatai Securities Co., Ltd. Xiamen Xihe Road Securities Office, with a buying amount of 5.6607 million yuan, while the largest selling brokerage was Dongfang Caifu Securities Co., Ltd. Lhasa Tuanjie Road Second Securities Office, with a selling amount of 6.3389 million yuan [2] - Over the past six months, the stock has appeared on the trading list eight times, with an average price drop of 4.65% the day after being listed and an average drop of 11.42% over the following five days [2]
XD中科美(835892) - 投资者关系活动记录表
2025-05-26 12:40
Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 75.51 million yuan, representing a year-on-year growth of 8.66% [5] - The net profit attributable to shareholders was 5.06 million yuan, with a year-on-year increase of 10.43% [5] Group 2: Industry Trends - The medical instruments and equipment manufacturing industry is experiencing steady growth, driven by continuous demand for low-temperature storage in life sciences and biopharmaceuticals [6] - The industry is shifting towards automation and intelligence, with government policies supporting domestic substitution and innovation in high-end medical devices [6] Group 3: Production Capacity and Investment Projects - The company operates four main production lines, including ultra-low temperature products and centrifuges, and has established additional production lines for various medical storage solutions [8] - Fundraising has been allocated to four projects: medical storage equipment, high-end medical devices, R&D center, and sales channel construction, with the sales channel project completed by the end of 2024 [8] Group 4: Strategic Business Planning - The company focuses on creating value for users and enhancing operational capabilities, with a strategy centered on deepening sample library ecosystems and expanding laboratory equipment offerings [9] - Continuous innovation and quality upgrades of existing products are prioritized, alongside the development of comprehensive solutions to facilitate technology transfer [9]
中科美菱(835892) - 关于注销部分募集资金专户的公告
2025-05-22 16:00
支行、合肥科技农村商业银行股份有限公司怀宁路支行、中国银行股份有限公司 舒城支行、中国光大银行合肥长江西路支行、杭州银行股份有限公司合肥分行分 别签订了《募集资金三方监管协议》。 证券代码:835892 证券简称:中科美菱 公告编号:2025-058 中科美菱低温科技股份有限公司 关于注销部分募集资金专户的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意中科美菱低温科技股份有限公司向 不特定合格投资者公开发行股票注册的批复》(证监许可[2022]2182 号),公司 首次公开发行 24,182,734 股人民币普通股股票(A 股),每股面值 1 元,发行价 格人民币 16 元/股,募集资金合计人民币 386,923,744.00 元。本次募集资金应 支付承销费用、保荐费用人民币 19,407,867.71 元(不含税),其中公司募集资 金到账前已使用自有资金支付保荐费用人民币 943,396.23 元(不含税),另 18,464,471.4 ...
中科美菱(835892) - 2024年年度权益分派实施公告
2025-05-18 16:00
证券代码:835892 证券简称:中科美菱 公告编号:2025-057 中科美菱低温科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 中科美菱低温科技股份有限公司 2024 年年度权益分派方案已获 2025 年 4 月 11 日召开的股东会审议通过,本次实施分配方案距离股东会审议通过的时间未 超过两个月。 现将权益分派事宜公告如下: 本次权益分派基准日合并报表归属于母公司的未分配利润为 107,521,201.21 元,母公司未分配利润为 116,257,816.90 元。本次权益分派共计派发现金红利 7,738,474.72 元。 一、权益分派方案 1、本公司 2024 年年度权益分派方案为: 以公司现有总股本 96,730,934 股为基数,向全体股东每 10 股派 0.800000 元 人民币现金。 2、扣税说明 (1)个人股东、投资基金适用股息红利差别化个人所得税政策, 个人股东、 投资基金持股 1 个月(含 1 个月)以内,每 10 股补缴税款 ...
中科美菱(835892) - 关于使用自有闲置资金购买理财产品的进展公告
2025-05-13 16:00
证券代码:835892 证券简称:中科美菱 公告编号:2025-055 中科美菱低温科技股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 (一)购买理财产品的审议情况 为提高公司资金使用效益,增加现金资产收益,实现股东利益最大化,公司 第三届董事会第三十一次会议、2024 年第二次临时股东大会,审议通过了《关 于使用自有闲置资金进行投资理财的议案》,在保证日常经营运作资金需求、有 效控制投资风险的前提下,公司及下属子公司拟使用自有闲置资金最高不超过 2 亿元人民币(该额度可以滚动使用)进行银行理财产品投资,投资期限为自 2024 年第二次临时股东大会审议通过之日起一年内有效。 具体内容详见公司于 2024 年 12 月 11 日、12 月 27 日在北京证券交易所网 站披露的《关于使用自有闲置资金进行投资理财的公告》(公告编号:2024-071) 《2024 年第二次临时股东大会决议公告》(公告编号:2024-074)。 (二)本次购买理财披露的标准 根据《北京证券交易所股票上市规则》的相关规定,上市公司以自有资金实 际购买理财产品,交易的成交金额占上市公司最近一期经审计净资产的 10%以 上,且超过 ...
中科美菱(835892) - 关于使用部分闲置募集资金进行现金管理的进展公告
2025-05-13 16:00
为提高募集资金使用效率,本着股东利益最大化的原则,公司第三届董事会 第三十一次会议、2024 年第二次临时股东大会,审议通过了《关于使用部分募 集资金进行现金管理的议案》,在确保不影响募集资金投资项目正常实施以及确 保募集资金安全的前提下,公司及下属子公司使用最高不超过 25,000 万元(该 额度可以循环滚动使用)闲置募集资金购买安全性高、流动性好、低风险、可保 障本金安全的理财产品,使用期限为自 2024 年第二次临时股东大会审议通过之 日起 12 个月内有效。 关于使用部分闲置募集资金进行现金管理的进展公告 证券代码:835892 证券简称:中科美菱 公告编号:2025-056 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权募集资金现金管理情况 中科美菱低温科技股份有限公司 (一)现金管理的审议情况 (一)本次募集资金购买现金管理产品的基本情况 | 受托方 | 产品类 | 产品名称 | 产品金额 | 预计年化收 | 产品期限 | 收益 | 投资方向 | 资金 | | --- | --- ...
中科美菱(835892) - 2025年第一次临时股东会决议公告
2025-05-07 16:00
本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 (一)会议召开情况 1.会议召开时间:2025 年 5 月 8 日 证券代码:835892 证券简称:中科美菱 公告编号:2025-048 中科美菱低温科技股份有限公司 2025 年第一次临时股东会决议公告 2.会议召开地点:安徽省合肥市经济技术开发区紫石路 1862 号公司会议室 3.会议召开方式:现场投票和网络投票相结合的方式 4.会议召集人:董事长 5.会议主持人:董事长吴定刚先生 6.召开情况合法、合规、合章程性说明: 本次股东会的召开符合《公司法》等有关法律、法规及《公司章程》的规 定。 (二)会议出席情况 出席和授权出席本次股东会的股东共 10 人,持有表决权的股份总数 68,628,288 股,占公司有表决权股份总数的 70.9476%。 其中通过网络投票参与本次股东会的股东共 2 人,持有表决权的股份总数 500,200 股,占公司有表决权股份总数的 0.5171%。 (三)公司董事、监事、高级管理人员出席或列席股东 ...